Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Monitoring drug treatment.

Literature DB >> 14630730

Monitoring drug treatment.

Munir Pirmohamed, Robin E Ferner.

Abstract

Mesh：

Year: 2003 PMID： 14630730 PMCID： PMC274045 DOI： 10.1136/bmj.327.7425.1179

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

12 in total

1. Side effects of statins: hepatitis versus "transaminitis"-myositis versus "CPKitis".

Authors: Carlos A Dujovne
Journal: Am J Cardiol Date: 2002-06-15 Impact factor: 2.778

2. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting.

Authors: C Christopher Smith; Lana I Bernstein; Roger B Davis; David M Rind; Robert H Shmerling
Journal: Arch Intern Med Date: 2003-03-24

Review 3. Update on the U.S. Food and Drug Administration regulatory approach to over-the-counter cholesterol-lowering drugs.

Authors: D G Orloff
Journal: Am J Cardiol Date: 1998-04-23 Impact factor: 2.778

4. Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis.

Authors: G Honigfeld
Journal: Psychiatr Serv Date: 1996-01 Impact factor: 3.084

5. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism.

Authors: Clive Kearon; Jeffrey S Ginsberg; Michael J Kovacs; David R Anderson; Philip Wells; Jim A Julian; Betsy MacKinnon; Jeffrey I Weitz; Mark A Crowther; Sean Dolan; Alexander G Turpie; William Geerts; Susan Solymoss; Paul van Nguyen; Christine Demers; Susan R Kahn; Jeannine Kassis; Marc Rodger; Julie Hambleton; Michael Gent
Journal: N Engl J Med Date: 2003-08-14 Impact factor: 91.245

6. The safety of spironolactone treatment in patients with heart failure.

Authors: C Anton; A R Cox; R D S Watson; R E Ferner
Journal: J Clin Pharm Ther Date: 2003-08 Impact factor: 2.512

7. Mechanism of clozapine-induced agranulocytosis : current status of research and implications for drug development.

Authors: M Pirmohamed; K Park
Journal: CNS Drugs Date: 1997-02 Impact factor: 5.749

8. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.

Authors:
Journal: Arch Intern Med Date: 1996-02-26

9. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.

Authors: J M Alvir; J A Lieberman; A Z Safferman; J L Schwimmer; J A Schaaf
Journal: N Engl J Med Date: 1993-07-15 Impact factor: 91.245

10. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors:
Journal: Lancet Date: 2002-07-06 Impact factor: 79.321

14 in total

1. Monitoring drug therapy.

Authors: Thierry Buclin; Verena Gotta; Aline Fuchs; Nicolas Widmer; Jeffrey Aronson
Journal: Br J Clin Pharmacol Date: 2012-06 Impact factor: 4.335

2. Oversight: a retrospective study of biochemical monitoring in patients beginning antihypertensive drug treatment in primary care.

Authors: Jamie J Coleman; Sarah E McDowell; Stephen J W Evans; Paramjit S Gill; Robin E Ferner
Journal: Br J Clin Pharmacol Date: 2010-07 Impact factor: 4.335

Monitoring drug treatment.

1. Side effects of statins: hepatitis versus "transaminitis"-myositis versus "CPKitis".

2. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting.

Review 3. Update on the U.S. Food and Drug Administration regulatory approach to over-the-counter cholesterol-lowering drugs.

4. Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis.

5. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism.

6. The safety of spironolactone treatment in patients with heart failure.

7. Mechanism of clozapine-induced agranulocytosis : current status of research and implications for drug development.

8. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.

9. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.

10. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

1. Monitoring drug therapy.

2. Oversight: a retrospective study of biochemical monitoring in patients beginning antihypertensive drug treatment in primary care.

3. Emergency re-admissions to hospital due to adverse drug reactions within 1 year of the index admission.

Review 4. Monitoring in chronic disease: a rational approach.

5. The quality of information on monitoring for haematological adverse drug reactions.

Review 6. Best practice in primary care pathology: review 1.

7. Monitoring therapy.

Review 8. Monitoring for adverse drug reactions.

9. Drug-drug interactions and adverse drug reactions: separating the wheat from the chaff.

Review 10. Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review.